___

• [1] B. M. Sibai, “Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count,” Obstet. Gynecol., vol. 103, no. 5 I, pp. 981–991, 2004, doi: 10.1097/01.AOG.0000126245.35811.2a.
• [2] H. Wulf, “[Anesthesia and intensive therapy of pregnant women with the HELLP syndrome],” Anaesthesist, vol. 39, no. 2, pp. 117–121, Feb. 1990, Accessed: Jan. 26, 2022. [Online]. Available: https://europepmc.org/article/med/2310003.
• [3] D. Ben Letaifa et al., “[Maternal and perinatal morbidity and mortality associated with hellp syndrome] .,” Ann. Fr. Anesth. Reanim., vol. 19, no. 10, pp. 712–718, Dec. 2000, doi: 10.1016/S0750-7658(00)00313-0.
• [4] R. K. S. Whitta, D. J. A. Cox, and S. V. Mallett, “Thrombelastography reveals two causes of haemorrhage in HELLP syndrome,” Br. J. Anaesth., vol. 74, no. 4, pp. 464–468, Apr. 1995, doi: 10.1093/BJA/74.4.464.
• [5] C. M. Mihu and A. Seicean, “HELLP syndrome-A multisystemic disorder View project SONODIG View project,” Accessed: Jan. 26, 2022. [Online]. Available: https://www.researchgate.net/publication/5658642.
• [6] R. D’Anna, “[The HELLP syndrome. Notes on its pathogenesis and treatment],” Minerva Ginecol., vol. 48, no. 4, pp. 147–154, Apr. 1996, Accessed: Jan. 26, 2022. [Online]. Available: https://europepmc.org/article/med/8767557.
• [7] B. Haddad, J. R. Barton, J. C. Livingston, R. Chahine, and B. M. Sibai, “Risk factors for adverse maternal outcomes among women with HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome,” Am. J. Obstet. Gynecol., vol. 183, no. 2, pp. 444–448, Aug. 2000, doi: 10.1067/MOB.2000.105915.
• [8] S. mei Wan, Y. hong Yu, Y. ying Huang, and G. dong Su, “[Morbidity regularity of severe complications of hypertensive disorder complicating pregnancy in clinics].,” Zhonghua Fu Chan Ke Za Zhi, vol. 42, no. 8, pp. 510–514, Aug. 2007, Accessed: Jan. 26, 2022. [Online]. Available: https://europepmc.org/article/med/17983486.
• [9] M. Armagan, O. Selen, O. Hülya, and U. Hasan Bozkaya, “Maternal outcome in HELLP syndrome requiring intensive care management in a Turkish hospital.”
• [10] C. M. Isler, B. K. Rinehart, D. A. Terrone, R. W. Martin, E. F. Magann, and J. N. Martin, “Maternal mortality associated with HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome,” Am. J. Obstet. Gynecol., vol. 181, no. 4, pp. 924–928, Oct. 1999, doi: 10.1016/S0002-9378(99)70343-1.
• [11] N. Prakash, T. McLeod, and F. Gao Smith, “The effects of remifentanil on haemodynamic stability during rigid bronchoscopy,” Anaesthesia, vol. 56, no. 6, pp. 576–580, Jan. 2001, doi: 10.1046/J.1365-2044.2001.01913-3.X.
• [12] S. P. Ankichetty et al., “Regional anesthesia in patients with pregnancy induced hypertension,” J. Anaesthesiol. Clin. Pharmacol., vol. 29, no. 4, p. 435, Oct. 2013, doi: 10.4103/0970-9185.119108.
• [13] P. J. Neligan and J. G. Laffey, “Clinical review: Special populations - critical illness and pregnancy,” Crit. Care, vol. 15, no. 4, pp. 1–10, Aug. 2011, doi: 10.1186/CC10256/TABLES/4.
• [14] L. J. Santos Iglesias, J. L. Sánchez, J. A. Reboso Morales, C. Mesa del Castillo Payá, L. Fuster Puigdoménech, and F. González Miranda, “Anestesia general con remifentanilo en dos casos de cesárea urgente,” Rev. esp. anestesiol. reanim, pp. 244–247, 2001.
• [15] A. Kapila et al., “Measured Context-sensitive Half-times of Remifentanil and Alfentanil,” Anesthesiology, vol. 83, no. 5, pp. 968–975, Nov. 1995, doi: 10.1097/00000542-199511000-00009.
• [16] S. Aloizos et al., “HELLP syndrome: Understanding and management of a pregnancy-specific disease,” https://doi.org/10.3109/01443615.2013.775231, vol. 33, no. 4, pp. 331–337, May 2013, doi: 10.3109/01443615.2013.775231.